查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美肌少症治療市場預測至 2030 年 - 區域分析 - 按治療類型和配銷通路
市場調查報告書
商品編碼
1562379

北美肌少症治療市場預測至 2030 年 - 區域分析 - 按治療類型和配銷通路

North America Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 72 Pages | 訂單完成後即時交付

價格

2022年北美肌肉減少症治療市場估值為14.5112億美元，預計2030年將達到22.7385億美元；預計2022年至2030年複合年成長率為5.8%。

老年人口激增推動北美肌少症治療市場

老年人群容易出現肌少症、骨科疾病、代謝紊亂和神經系統疾病等。肌少症是一種老年疾病，其特徵是骨骼肌質量和強度逐漸喪失。它與較高的不利健康結果風險有關，例如跌倒、殘疾、收容、生活品質差和死亡。已開發國家的老年人口正在迅速增加。根據世界衛生組織(WHO) 的數據，到2050 年，全球老化人口可能會從2019 年的約10 億增加到約21 億。約1920年至2020年這100年間總人口成長速度快五倍。

老化導致肌肉量減少，這是身體組成的主要變化之一。老年人食物消耗的顯著下降是導致肌肉量損失的關鍵因素之一。根據美國國家醫學圖書館的數據，50-60歲年齡層的人每年損失近1.5%的肌肉力量，而60歲以後每年損失1-2%的肌肉量。肌肉少症盛行率較高。根據 Elsevier 2023 年 6 月發表的一篇文章，肌少症的盛行率從糖尿病患者的 18% 到無法治癒的食道癌患者的 66% 不等。因此，老年人口的增加對肌少症治療市場的成長做出了重大貢獻。

北美肌少症治療市場概述

北美的肌少症治療市場分為美國、加拿大和墨西哥。 2022 年，北美佔據全球市場的最大佔有率。此外，隨著老年人維生素 B12 和維生素 D 缺乏病例的增加，骨科疾病的盛行率激增，也推動了該地區的市場。

肌少症的盛行率因年齡和性別而異；居住在美國輔助生活設施或社區的老年人罹患這種疾病的風險較高。根據美國國立衛生研究院的數據，2019年美國肌肉減少症患者的預計住院費用為404億美元。患有肌少症的人每年比肌肉量和功能正常的人多支付 2,315 美元的住院費用；他們住院的可能性幾乎是沒有肌少症的人的兩倍。此外，骨骼肌損失減少 10% 可以預防肌少症可能的合併症，並為美國每年節省約 10 億美元的醫療費用。

北美肌少症治療市場收入及 2030 年預測（百萬美元）

北美肌少症治療市場區隔

北美肌少症治療市場按治療類型、配銷通路和國家分類。

根據治療類型，北美肌少症治療市場分為維生素 D 和鈣補充劑、蛋白質補充劑、維生素 B12 補充劑等。 2022 年，維生素 D 和鈣補充劑領域佔據北美肌少症治療市場最大佔有率。

在配銷通路方面，北美肌少症治療市場分為藥局、零售通路、線上通路等。 2022 年，藥局部門佔據北美肌少症治療市場最大佔有率。

依國家/地區分類，北美肌少症治療市場分為美國、加拿大和墨西哥。 2022 年，美國在北美肌少症治療市場佔有率中佔據主導地位。

Abbott Laboratories、Bayer AG、Metagenics LLC、Nestle Health Science SA、Novartis AG、Pfizer Inc、Sanofi SA、Amway Corp、GSK Plc 和 Makers Nutrition LLC 是北美肌肉減少症治療市場上的一些領先公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：北美肌少症治療市場 - 主要產業動態

  • 北美肌少症治療市場 - 主要產業動態
  • 市場促進因素
    • 老年人口激增
    • 成人營養不良和維生素缺乏症增加
  • 主要市場限制：
    • 無法直接干預
  • 主要市場機會：
    • 處於臨床試驗階段的產品
  • 未來趨勢：
    • 人們對肌少症的認知不斷提高
  • 促進因素和限制的影響：

第 5 章：肌少症治療市場 - 北美市場分析

  • 北美肌少症治療市場收入，2020 - 2030
  • 北美肌少症治療市場預測與分析

第 6 章：北美肌少症治療市場分析 - 按治療類型

  • 維生素 D 和鈣補充劑
  • 蛋白質補充劑
  • 維生素 B12 補充劑
  • 其他

第 7 章：北美肌少症治療市場分析 - 按配銷通路

  • 藥局
  • 零售通路
  • 線上通路
  • 其他

第 8 章：北美肌少症治療市場 - 國家分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

第 9 章：肌少症治療市場-產業格局

  • 概述
  • 肌少症治療市場的成長策略
  • 無機成長策略
    • 概述
  • 有機成長策略
    • 概述

第 10 章：公司簡介

  • Abbott Laboratories
  • Bayer AG
  • Metagenics LLC
  • Nestle Health Science SA
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Amway Corp
  • GSK Plc
  • Makers Nutrition LLC

第 11 章：附錄

Product Code: BMIRE00030523

The North America sarcopenia treatment market was valued at US$ 1,451.12 million in 2022 and is expected to reach US$ 2,273.85 million by 2030; it is estimated to register a CAGR of 5.8% from 2022 to 2030.

Upsurge in Geriatric Population Fuels North America Sarcopenia Treatment Market

The geriatric population is prone to sarcopenia, orthopedic disorders, metabolic disorders, and neurological disorders, among others. Sarcopenia is a geriatric illness characterized by a progressive loss of the mass and strength of skeletal muscles. It is associated with a higher risk of unfavorable health outcomes, e.g., falls, disabilities, institutionalization, poor quality of life, and mortality. The elderly populace is rising rapidly in developed countries. According to the World Health Organization (WHO), the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050. Also, according to the 2020 Census, the population of US 65 and older increased about five times faster than the total population during the 100 years between 1920 and 2020. In 2020, the number of older populations reached 55.8 million, or 16.8% of the total population of the US.

Aging results in a reduction in muscle mass as one of the major changes in body composition. A significant decline in food consumption among elderly people is one of the key factors causing the loss of muscle mass. According to the National Library of Medicine, people from the age group of 50-60 lose nearly 1.5% of muscle strength every year, while 1-2% of muscle mass is lost annually after the age of 60. Compared to general populations, elderly patients had a higher prevalence of sarcopenia. According to an article published in June 2023 in Elsevier, the prevalence of sarcopenia ranges from 18% in diabetic patients to 66% in those with incurable esophageal cancer. Hence, the rising elderly population contributes significantly to the sarcopenia treatment market growth.

North America Sarcopenia Treatment Market Overview

The sarcopenia treatment market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the global market in 2022. The sarcopenia treatment market growth in North America is attributed to the rising adoption of nutraceutical supplements for the treatment. In addition, the surging prevalence of orthopedic disorders with the increasing number of cases of vitamin B12 and vitamin D deficiency in the geriatric population fuels the market in this region.

Sarcopenia prevalence varies with age and gender; elderly people residing in assisted living facilities or communities in the US are at a higher risk of developing this condition. According to the National Institute of Health, in 2019, the anticipated hospitalization cost for persons with sarcopenia in the US was US$ 40.4 billion. People with sarcopenia pay US$ 2,315 more for hospital visits than people with normal muscle mass and function every year on average; they are almost twice as likely to be hospitalized than people without sarcopenia. Additionally, a 10% decrease in the loss of skeletal muscle can prevent the possible comorbidity of sarcopenia and save around US$ 1 billion in annual US medical care expenses.

North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

North America Sarcopenia Treatment Market Segmentation

The North America sarcopenia treatment market is categorized into treatment type, distribution channel, and country.

Based on treatment type, the North America sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest North America sarcopenia treatment market share in 2022.

In terms of distribution channel, the North America sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest North America sarcopenia treatment market share in 2022.

By country, the North America sarcopenia treatment market is segmented into the US, Canada, and Mexico. The US dominated the North America sarcopenia treatment market share in 2022.

Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, GSK Plc, and Makers Nutrition LLC are some of the leading companies operating in the North America sarcopenia treatment market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Sarcopenia Treatment Market - Key Industry Dynamics

  • 4.1 North America Sarcopenia Treatment Market - Key Industry Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Upsurge in Geriatric Population
    • 4.2.2 Rise in Malnutrition and Vitamin Deficiency Among Adults
  • 4.3 Key Market Restraints:
    • 4.3.1 Unavailability of Direct Interventions
  • 4.4 Key Market Opportunities:
    • 4.4.1 Products in Clinical Trial Phases
  • 4.5 Future Trends:
    • 4.5.1 Rising Awareness About Sarcopenia
  • 4.6 Impact of Drivers and Restraints:

5. Sarcopenia Treatment Market - North America Market Analysis

  • 5.1 North America Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
  • 5.2 North America Sarcopenia Treatment Market Forecast and Analysis

6. North America Sarcopenia Treatment Market Analysis - By Treatment Type

  • 6.1 Vitamin D and Calcium Supplement
    • 6.1.1 Overview
    • 6.1.2 Vitamin D and Calcium Supplement : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 6.2 Protein Supplement
    • 6.2.1 Overview
    • 6.2.2 Protein Supplement : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Vitamin B12 Supplement
    • 6.3.1 Overview
    • 6.3.2 Vitamin B12 Supplement: North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Others
    • 6.4.1 Overview
    • 6.4.2 Others : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)

7. North America Sarcopenia Treatment Market Analysis - By Distribution Channel

  • 7.1 Pharmacies
    • 7.1.1 Overview
    • 7.1.2 Pharmacies : North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Retail Channels
    • 7.2.1 Overview
    • 7.2.2 Retail Channels : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Online Channels
    • 7.3.1 Overview
    • 7.3.2 Online Channels : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others : North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

8. North America Sarcopenia Treatment Market - Country Analysis

  • 8.1 North America
    • 8.1.1 North America Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
      • 8.1.1.1 North America Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
      • 8.1.1.2 United States Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.2.1 United States Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.2.2 United States Sarcopenia Treatment Market Breakdown by Distribution Channel
      • 8.1.1.3 Canada Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.3.1 Canada Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.3.2 Canada Sarcopenia Treatment Market Breakdown by Distribution Channel
      • 8.1.1.4 Mexico Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.4.1 Mexico Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.4.2 Mexico Sarcopenia Treatment Market Breakdown by Distribution Channel

9. Sarcopenia Treatment Market-Industry Landscape

  • 9.1 Overview
  • 9.2 Growth Strategies in the Sarcopenia Treatment Market
  • 9.3 Inorganic Growth Strategies
    • 9.3.1 Overview
  • 9.4 Organic Growth Strategies
    • 9.4.1 Overview

10. Company Profiles

  • 10.1 Abbott Laboratories
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 Bayer AG
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 Metagenics LLC
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Nestle Health Science SA
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 Novartis AG
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 Pfizer Inc
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 Sanofi SA
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Amway Corp
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments
  • 10.9 GSK Plc
    • 10.9.1 Key Facts
    • 10.9.2 Business Description
    • 10.9.3 Products and Services
    • 10.9.4 Financial Overview
    • 10.9.5 SWOT Analysis
    • 10.9.6 Key Developments
  • 10.10 Makers Nutrition LLC
    • 10.10.1 Key Facts
    • 10.10.2 Business Description
    • 10.10.3 Products and Services
    • 10.10.4 Financial Overview
    • 10.10.5 SWOT Analysis
    • 10.10.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners
  • 11.2 Glossary of Terms

List Of Tables

  • Table 1. North America Sarcopenia Treatment Market Segmentation
  • Table 2. Sarcopenia Drug Under Clinical Development
  • Table 3. North America Sarcopenia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. North America Sarcopenia Treatment Market - Revenue and Forecast to 2030 (US$ Million) - By Treatment Type
  • Table 5. North America Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Million) - By Distribution Channel
  • Table 6. North America Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Country
  • Table 7. United States Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 8. United States Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 9. Canada Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 10. Canada Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 11. Mexico Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 12. Mexico Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 13. Recent Inorganic Growth Strategies in the Sarcopenia Treatment Market
  • Table 14. Recent Organic Growth Strategies in the Sarcopenia Treatment Market
  • Table 15. Glossary of Terms, Sarcopenia Treatment Market

List Of Figures

  • Figure 1. North America Sarcopenia Treatment Market Segmentation, By Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. North America Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
  • Figure 4. North America Sarcopenia Treatment Market Share (%) - By Treatment Type, 2022 and 2030
  • Figure 5. Vitamin D and Calcium Supplement : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 6. Protein Supplement : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 7. Vitamin B12 Supplement: North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 8. Others : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 9. North America Sarcopenia Treatment Market Share (%) - By Distribution Channel, 2022 and 2030
  • Figure 10. Pharmacies : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 11. Retail Channels : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 12. Online Channels : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 13. Others : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 14. North America Sarcopenia Treatment Market Revenue, by Key Countries, (2022) (US$ Mn)
  • Figure 15. North America Sarcopenia Treatment Market Breakdown by Key Countries, 2022 and 2030 (%)
  • Figure 16. United States Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 17. Canada Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 18. Mexico Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 19. Growth Strategies in the Sarcopenia Treatment Market